• BioElectronics entered an execution-phase distribution and licensing deal with Electrome to market FDA-cleared pulsed shortwave therapy products in North America.
• Manufacturing started following an initial purchase order for a launch under Electrome’s PAINKILLER consumer platform.
• Electrome plans an AI-driven direct-to-consumer rollout, prioritizing digital marketing, e-commerce scaling, consumer education, logistics, and customer support.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioElectronics Corporation published the original content used to generate this news brief on June 17, 2026, and is solely responsible for the information contained therein.